This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Pliant Therapeutics’s 8K filing here.
Pliant Therapeutics Company Profile
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Read More
- Five stocks we like better than Pliant Therapeutics
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- Merck: 4 No-Brainer Reasons to Buy This Dip
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
